Torrent Pharmaceuticals reported a 55% YoY rise in Q1 FY27 revenue to ₹4,921 crore, while the profit after tax (PAT) increased 3.3% to ₹566 crore. Operating EBITDA grew 61% with margin expanding to 33.8%. The company also recorded strong growth across India, Brazil and the US, while FII holdings increased to 17.97% during the July 2026 quarter.